In 2017, after almost 10 years, a sub-analysis showed a potential benefit in slowing cognitive decline in ApoE4 homozygotes, especially in mild AD [204], with lower rates on hippocampal atrophy in ApoE4/4 carriers treated with tramiprosate [205]. Here, APOE is linked to hippocampal atrophy.